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We performed a detailed cancer VS normal analysis to explore the expression and
prognostic value of minichromosome maintenance (MCM) proteinsin human sarcoma.
The mRNA expression levels of the MCM family genes in sarcoma were analyzed using
data from ONCOMINE, GEPIA and CCLE databases. KEGG database was used to analyze
the function of MCM2–7 complex in DNA replication and cell cycle. QRT-PCR and western
blot were used to confirm the differential expression of key MCMs in osteosarcoma cell lines.
Cell Counting Kit-8 and flow cytometry method were used to detect the cell proliferation and
apoptosis of hFOB1.19 cells. The results showed that MCM1–7 and MCM10 were all
upregulated in sarcoma in ONCOMINE database. MCM2, and MCM4–7 were highly
expressed in sarcoma in GEPIA database. Moreover, all these ten factors were highly
expressed in sarcoma cell lines. Furthermore, we analyzed the prognostic value of MCMs for
sarcoma in GEPIA and found that MCM2, MCM3, MCM4, and MCM10 are prognostic
biomarkers for human sarcoma. Analysis results using KEGG datasets showed that MCM4
and MCM6–7 constituted a core structure of MCM2-7 hexamers. We found that AzadC
treatment and overexpression of MCM4 significantly promoted hFOB1.19 cell proliferation
and inhibited apoptosis. The present study implied that MCM2–4 and 10 are potential
biomarkers for the prognosis of sarcoma. The prognostic role of MCM4may be attributable
to the change in its DNA methylation patterns.
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INTRODUCTION
Sarcomas are malignant tumors derived from mesenchymal tissues (including connective tissue and
muscle), and they mostly occur in the skin, subcutaneous, periosteum and both ends of long bones.
Sarcomas can be divided into soft tissue sarcoma and osteosarcoma. Osteosarcoma is more common in
adolescents and occurs in the metaphysis of the extremities, especially the distal femur and proximal tibia.
Common symptoms of osteosarcoma include pain, swelling, numbness, varicose veins, and even
pathological fractures. Osteosarcoma is highly malignant, grows rapidly, and often spreads to the lungs
through blood. Some sarcomas, in contrast, are more common in the elderly, such as liposarcoma and
leiomyosarcoma, of which the clinical manifestations are often non-specific and are often related to the
degree of the malignancy. Soft tissue sarcomas account for about 0.8% of human malignant tumors, with
the annual incidence rate of about 2.38/100,000 in China and increasing significantly with age. The most
common site of soft tissue sarcomas is limb, accounting for 53%, followed by retroperitoneum (19%), trunk
(12%), head and neck (11%). The most common primary bone malignant tumor is classic osteosarcoma,
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which accounts for about 0.2% of human malignant tumors. The
most common sites of incidence are the distal femur and proximal
tibia, followed by In the proximal humerus, osteosarcomas in these
three locations account for approximately 85% of all osteosarcomas.
Now, sarcomas are divided into two categories at the molecular level:
1) genetically complex, high mutation burden, and complex
karyotype; and 2) genetically simple, with a single disease-specific
translocation, mutation, or amplification in a relatively static genome
background, mutation or amplification. This histological and
molecular heterogeneity makes sarcomas particularly difficult to
diagnose. Therefore, new biomarkers are needed as prognostic
indicators to guide individualized treatment and improve patients’
prognosis (Dancsok et al., 2017).
Minichromosome maintenance proteins (MCMs) comprised
ten proteins, which play essential roles in DNA replication and cell
cycle progression (Maiorano et al., 2006; Li et al., 2019). They were
first discovered in Saccharomyces cerevisiae and identified as
essential factors for the maintenance of extra-chromosomal
DNA (Ishimi, 2018). MCM1 influences the process of cell cycle,
growth, differentiation, and apoptosis by regulating the activation
of multiple genes. It belongs to MADS box transcription factor
family (Pramila et al., 2002). TheMCM2-7 form a heterohexameric
complex that serves as a DNA duplicating helicase, which unwinds
the DNA duplex template during DNA replication (Fei and Xu,
2018; Suzuki et al., 2019). MCM8 and nine were reported to make
up the CMG complex with Cdt1 and GINS. (Griffin and Trakselis,
2019). MCM10 plays an important role in the initiation of DNA
replication and elongation (Baxley and Bielinsky, 2017). As same as
many DNA replication proteins, MCM proteins were reported to
play an important role in cancer development (Yu et al., 2020).
MCMs has been detected that were overexpressed in multiple
cancer tissues and carcinoma cell lines, such as lymphomas
(Marnerides et al., 2011; Rusiniak et al., 2012), brain tumors
(Winther and Torp, 2017; Cai et al., 2018), gastrointestinal tract
tumors (Giaginis et al., 2009; Shomori et al., 2010; Peng et al.,
2016), breast cancer (Wojnar et al., 2011), prostate cancer (Stewart
et al., 2017), renal cell carcinoma (Zhong et al., 2017), and lung
squamous cell carcinoma (Wu et al., 2018). However, the role of
MCM family members in the development of sarcoma has not
been fully understood, and its prognostic value for sarcoma is still
unknown. In this present study, we used database research and
bioinformatic analysis to assess the expression of MCMs in
sarcoma and analyze its prognostic value for sarcoma.
METHODS
Oncomine Analysis
Oncomine is currently the world’s largest cancer gene chip
database and integrated data mining platform. It aims to mine
cancer genetic information. It integrates RNA and DNA-seq data
from GEO, TCGA and published literature sources, and has the
most complete cancer mutation spectrum, gene expression data
and related clinical information. It can be used to discover new
biomarkers and new therapeutic targets.
With using Oncomine datasets, we performed multiple
expression analyses of MCMs in sarcoma and normal samples.
The p value was generated by using a Students’ t-test. We defined
the cut-off of p-value and fold change as 0.01 and 2, respectively. It
was also used to find the co-expression genes ofMCMs in sarcoma.
Gene Expression Profile Interactive
Analysis Dataset
GEPIA (Gene Expression Profile Interactive Analysis) is a web-
based tool for delivering fast and customizable functionalities
based on TCGA and GTEx data. In our study, Data from the
GEPIA datasets were used to analyze the different expression
levels of MCMs in sarcoma and normal tissues. We also analyzed
the correction between MCMs in sarcoma by using the GEPIA
dataset. In order to explore the prognostic value of MCMs in
sarcoma patients, GEPIA was also used to analyze the association
of the expression levels of MCMs with the OS and DFS.
Cancer Cell Line Encyclopedia Dataset
CCLE (Cancer Cell Line Encyclopedia) is a tumor genomics
research project led by the Broad Institute. It collects and sorts
out the omics data of 1,457 cell lines. We analyzed the expression
levels of the tenMCMs in sarcoma cell lines, by using CCLE dataset.
Kyoto Encyclopedia of Genes and Genomes
Dataset
KEGG (Kyoto Encyclopedia of Genes and Genomes) is a practical
database resource for understanding advanced functions and
biological systems (such as cells, organisms, and ecosystems),
genome sequencing and other high-throughput experimental
technologies generated from molecular level information,
especially large molecular data sets. In our study, we used data
from the KEGG to analyze the functional role of MCM2–7
complex in DNA replication and cell cycle.
CpG Island Prediction
We obtained the human MCM4 (ENSG00000104738) sequence
from Ensembl genome browser (http://asia.ensembl.org/index.
html). We used MethPrimer software (http://www.urogene.org/
methprimer) to analyze CpG islands, and to detect the first exon
sequence. We predict the candidate transcription factor by
JASPAR (http://jaspar.binf.ku.dk/).
Cell Culture
We purchase hFOB1.19 cell line in Chinese Science Institute
(Shanghai, China). hFOB1.19 cells were cultured in Roswell Park
Memorial Institute (RPMI) 1,640 medium (HyClone, Logan, UT,
United States), containing 10% fetal bovine serum (FBS) (Sijiqing,
Hangzhou, China).
Total RNA Isolation and qRT-PCR
We isolate RNA from 100 mg of tissue (liquid nitrogen grounding
method performed before RNA extraction) and 2 × 106 cells by
TRIzol Reagent (Invitrogen, Carlsbad, CA, United States). We
performed RNA qualification and quantification using Biotek
(Winooski, VT, United States). A total of 2 μg RNA was reverse
transcribed to cDNA with Superscript III Reverse Transcriptase
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(Invitrogen). Quantitative real-time PCRs (qRT-PCRs) were
conducted in an ABI StepOnePlus instrument, with the SYBR
(TaKaRa) system, and a thermal profile of 40 cycles of 95°C for
10 s and 58°C for 30 s. All of the results were standardized to the
expression level of the housekeeping gene, β-actin. Relative
mRNA expression levels were calculated using 2−△△ CT.
Western Blot
We washed the monolayer cells with 1× PBS and extracted the
proteins by using RIPA lysis buffer. All the specimens were
centrifuged (10000 g, 4°C for 10 min). Protein concentration
was measured using BCA protein assay kit (Beyotime).
Proteins were resolved by 10% SDS-PAGE and then
transferred to PVDF membranes which was blocked using 5%
non-fat milk in 1× TBS mixed with Tween-20. After that, the
membrane was incubated overnight with anti-MCM2/4 antibody
(1:2000, abcam) at 4°C. The PVDF membrane was washed using
1 × TBS-T for 15 min for 3 times. Secondary anti-rabbit IgG
antibody was used to incubate (1:10,000, biosharp) for 1 h.
Electrochemiluminescence was added to PVDF membrane and
the membrane was exposed on an X-ray film.
Cell Proliferation Assay
We analyzed cell proliferation by the Cell Counting Kit-8 (Dojindo).
After 2 days, hFOB1.19 cells were inducible. AzadC-treated cells were
then incubated for another 24 h. A BioTekmicroplate reader was used
to measure the optical density of each group.
Cell Apoptosis Assay
We analyzed the hFOB1.19 cell apoptosis using flow cytometry
method (FCM). We collected the cells 2 days after treatment with
AzadC, washed with PBS, and suspended in 500 μL binding
buffer. The cells were incubated with annexin V at room
temperature for 10 min and stained with PI, and then
analyzed by FCM for relative quantitative apoptosis.
Statistics
The data were presented as mean ± SD and statistical differences
were determined with Student’s t test. In the presented study, the
experiments conducted have been repeated for 3 times. The
representative experiments were shown in results. Significant
differences were defined at p < 0.05.
RESULTS
Transcriptional Levels of Minichromosome
Maintenance in Patients With Sarcoma
Previous studies have identified ten MCM factors in eukaryotic
cells and archaea (Maiorano et al., 2006). In the present study, we
used ONCOMINE database to compare the transcription levels of
MCMs in cancer and normal tissues. The results showed that
MCMs were generally upregulated in various of tumors. In
sarcoma, most of MCM members were highly expressed in
cancer tissues, except for MCM8 and MCM9 (Figure 1). The
mRNA expression levels of MCMs were showed in Table 1. In the
datasets of Detwiller Sarcoma (Detwiller et al., 2005), compared
with normal tissues, MCM1 was overexpressed in
leiomyosarcoma with a fold change of 2.063 (Table 1).
Quade Uterus datasets (Quade et al., 2004) showed that
MCM2 was overexpressed in uterine corpus leiomyosarcoma
with a fold change of 26.250. The datasets of Barretina
Sarcoma (Barretina et al., 2010) also showed the increased
expression of MCM2. The fold change of MCM2 in patients
with pleomorphic liposarcoma, myxofibrosarcoma,
leiomyosarcoma, myxoid/round cell liposarcoma and
dedifferentiated liposarcoma was 3.538, 3.819, 4.437, 3.012,
and 2.539, respectively. Using datasets of Detwiller Sarcoma,
MCM2 was also found to be overexpressed in leiomyosarcoma
(fold change  7.904), fibrosarcoma (fold change  4.867) and
malignant fibrous histiocytoma (fold change  4.180) compared
with normal samples (Table 1).
Using Barretina Sarcoma’s datasets, MCM3 was found to be
overexpressed in pleomorphic liposarcoma (fold change  2.316),
myxoid/round cell liposarcoma (fold change  2.769),
myxofibrosarcoma (fold change  2.122) and leiomyosarcoma
(fold change  2.212) when compared with normal samples.
MCM3 was also overexpressed in fibrosarcoma with a fold
change of 2.979 and synovial sarcoma with a fold change of
2.167, reported in Detwiller Sarcoma (Table 1).
Using datasets of Barretina Sarcoma, compared with normal
samples, MCM4 was overexpressed in pleomorphic liposarcoma,
myxofibrosarcoma, dedifferentiated liposarcoma,
leiomyosarcoma and myxoid/round cell liposarcoma, with the
fold change of 3.142, 3.455, 2.195, 3.042, and 2.227 respectively.
In Detwiller Sarcoma’s datasets, MCM4 was also showed to be
overexpressed in pleomorphic liposarcoma (fold change 
13.735), fibrosarcoma (fold change  10.126), malignant
fibrous histiocytoma (fold change  10.011), synovial sarcoma
(fold change  3.401) and leiomyosarcoma (fold change  8.153),
compared with normal samples (Table 1).
Analysis using Barretina Sarcoma’s datasets found a higher
expression of MCM5 in pleomorphic liposarcoma (fold change 
3.772), leiomyosarcoma (fold change  3.538), myxoid/round cell
liposarcoma (fold change  2.817) and dedifferentiated liposarcoma
(fold change  2.536), when compared with normal samples. Using
Detwiller Sarcoma’s datasets, MCM5 was also found to be
overexpressed in malignant fibrous histiocytoma (fold change 
4.703) compared with normal samples. (Table 1).
Overexpression of MCM6 in sarcoma was also found in both
datasets. In Detwiller Sarcoma’s datasets, MCM6 was
overexpressed in leiomyosarcoma (fold change  5.847),
fibrosarcoma (fold change  5.500), malignant fibrous
histiocytoma (fold change  4.896) and synovial sarcoma (fold
change  4.175). In Barretina Sarcoma’s datasets, MCM6 was
overexpressed in pleomorphic liposarcoma (fold change  3.300),
myxofibrosarcoma (fold change  3.234), leiomyosarcoma (fold
change  3.034), dedifferentiated liposarcoma (fold change 
2.076) and myxoid/round cell liposarcoma (fold change  2.141)
compared with normal samples (Table 1).
Analyses using these two datasets also showed the
overexpression of MCM7 in sarcoma. Using Barretina
Sarcoma’s datasets, the results showed that MCM7 was higher
expressed in myxoid/round cell liposarcoma (fold change  3.047),
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pleomorphic liposarcoma (fold change  2.349), leiomyosarcoma
(fold change  2.288) andmyxofibrosarcoma (fold change  2.339)
compared with normal samples. Using Detwiller Sarcoma’s
datasets, the results showed the overexpression of MCM7 in
fibrosarcoma (fold change  2.236) compared with normal
samples (Table 1).
Overexpression of MCM10 was found in the analysis using
Detwiller Sarcoma’s datasets. TheMCM10 fold change of patients
with round cell liposarcoma, Malignant fibrous histiocytoma,
synovial Sarcoma and fibrosarcoma was 7.893, 7.758, 5.892, and
9.258, respectively (Table 1).
Association Between Minichromosome
Maintenance mRNA Levels and
Clinicopathological Parameters in Patients
With Sarcoma
The mRNA expression levels of MCM factors in sarcoma and
normal tissues were compared using GEPIA datasets. We found
that except for MCM1, all other MCM factors had higher
expression levels in sarcoma than in normal tissues (p < 0.05
for MCM2, MCM4, MCM5, MCM6 and MCM7)
(Figures 2A–L).
Minichromosome Maintenance Expression
in Sarcoma Cell Lines
CCLE was used to expand the detailed annotation process of the
preclinical human cancer models. We found that the ten MCM
family members were all highly expressed in sarcoma cell lines
(Figure 3).
The Prognostic Values of Minichromosome
Maintenance in Sarcoma
We investigated the prognostic role of the ten MCM factors in
sarcoma by using the GEPIA online service. The results showed
that high levels of MCM3 and MCM10 mRNA significantly
FIGURE 1 | The transcription levels of MCM factors in different types of cancers.
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decreased the over survival (OS) (p < 0.05) and disease-free
survival (DFS) (p < 0.05) of sarcoma patients (Figures 4A,B).
Moreover, high levels of MCM2 and MCM4 mRNA significantly
decreased the OS (p < 0.05) of sarcoma patients (Figure 4A). The
mRNA expression levels of other MCM factors had no
statistically significant effect on OS and DFS in patients with
sarcoma (Figures 4A,B). Therefore, MCM2,MCM3,MCM4, and
MCM10 were four potential biomarkers for the prognosis of
sarcoma and a higher expression indicates worse outcomes.
Kyoto Encyclopedia of Genes and Genomes
Analysis and Venn Diagram Analysis
We analyzed the pathways related to the function changes of
MCMs by using KEGG datasets. The results showed that
MCM2–7 proteins formed a heterohexamer complex and
participated in the initial step of DNA synthesis (Figure 5A).
The cell cycle pathway was involved in the tumorigenesis and
pathogenesis of sarcoma (Figure 5B). A venn diagram was used
TABLE 1 | The significant changes of MCMs expression in subgroups of sarcoma.
Gene ID Types of sarcoma vs. Normal Fold change p Value t Test Renfrences
MCM1 Leiomyosarcoma vs. Normal 2.063 9.03E-5 4.752 Detwiller sarcoma
MCM2 Uterine corpus leiomyosarcoma vs. Normal 26.250 3.47E-7 12.037 Quade uterus
Pleomorphic liposarcoma vs. Normal 3.538 5.71E-14 12.932 Barretina sarcoma
Myxofibrosarcoma vs. Normal 3.819 3.38E-16 14.472 Barretina sarcoma
Leiomyosarcoma vs. Normal 4.437 1.15E-13 11.848 Barretina sarcoma
Myxoid/Round cell liposarcoma vs. Normal 3.012 7.51E-13 13.922 Barretina sarcoma
Dedifferentiated liposarcoma vs. Normal 2.539 8.57E-13 10.845 Barretina sarcoma
Leiomyosarcoma vs. Normal 7.904 1.54E-7 8.860 Detwiller sarcoma
Fibrosarcoma vs. Normal 4.867 2.06E-6 6.741 Detwiller sarcoma
Malignant fibrous histiocytoma vs. Normal 4.180 1.05E-6 6.440 Detwiller sarcoma
MCM3 Pleomorphic liposarcoma vs. Normal 2.316 2.00E-13 12.368 Barretina sarcoma
Myxoid/Round cell liposarcoma vs. Normal 2.769 9.19E-14 13.442 Barretina sarcoma
Myxofibrosarcoma vs. Normal 2.122 1.02E-11 9.391 Barretina sarcoma
Leiomyosarcoma vs. Normal 2.212 9.93E-10 8.245 Barretina sarcoma
Fibrosarcoma vs. Normal 2.979 1.98E-7 8.423 Detwiller sarcoma
Synovial sarcoma vs. Normal 2.167 4.19E-5 6.349 Detwiller sarcoma
MCM4 Pleomorphic liposarcoma vs. Normal 3.142 3.36E-15 14.259 Barretina sarcoma
Myxofibrosarcoma vs. Normal 3.455 1.12E-15 12.861 Barretina sarcoma
Dedifferentiated liposarcoma vs. Normal 2.195 6.46E-14 10.370 Barretina sarcoma
Leiomyosarcoma vs. Normal 3.042 9.01E-11 9.360 Barretina sarcoma
Myxoid/Round cell liposarcoma vs. Normal 2.227 3.15E-10 9.407 Barretina sarcoma
Pleomorphic liposarcoma vs. Normal 13.735 1.34E-8 10.545 Detwiller sarcoma
Fibrosarcoma vs. Normal 10.126 2.41E-8 8.507 Detwiller sarcoma
Malignant fibrous histiocytoma vs. Normal 10.011 1.50E-8 8.331 Detwiller sarcoma
Synovial sarcoma vs. Normal 3.401 5.28E-7 7.400 Detwiller sarcoma
Leiomyosarcoma vs. Normal 8.153 2.50E-6 6.623 Detwiller sarcoma
MCM5 Pleomorphic liposarcoma vs. Normal 3.772 8.63E-10 10.061 Barretina sarcoma
Leiomyosarcoma vs. Normal 3.538 2.41E-9 8.260 Barretina sarcoma
Myxoid/Round cell liposarcoma vs. Normal 2.817 7.49E-8 8.303 Barretina sarcoma
Dedifferentiated liposarcoma vs. Normal 2.536 8.54E-7 8.457 Barretina sarcoma
Malignant fibrous histiocytoma vs. Normal 4.703 8.32E-5 4.561 Detwiller sarcoma
MCM6 Leiomyosarcoma vs. Normal 5.847 3.58E-7 8.247 Detwiller sarcoma
Fibrosarcoma vs. Normal 5.500 5.30E-7 7.678 Detwiller sarcoma
Malignant fibrous histiocytoma vs. Normal 4.896 7.34E-7 6.930 Detwiller sarcoma
Synovial sarcoma vs. Normal 4.175 2.67E-5 6.725 Detwiller sarcoma
Pleomorphic liposarcoma vs. Normal 3.300 3.76E-12 10.849 Barretina sarcoma
Myxofibrosarcoma vs. Normal 3.234 3.06E-15 12.962 Barretina sarcoma
Leiomyosarcoma vs. Normal 3.034 1.41E-12 10.712 Barretina sarcoma
Dedifferentiated liposarcoma vs. Normal 2.076 2.14E-10 10.804 Barretina sarcoma
Myxoid/Round cell liposarcoma vs. Normal 2.141 2.91E-10 9.875 Barretina sarcoma
MCM7 Myxoid/Round cell liposarcoma vs. Normal 3.047 1.35E-10 12.092 Barretina sarcoma
Pleomorphic liposarcoma vs. Normal 2.349 1.27E-8 9.695 Barretina sarcoma
Leiomyosarcoma vs. Normal 2.288 9.17E-9 8.526 Barretina sarcoma
Myxofibrosarcoma vs. Normal 2.339 9.65E-9 9.552 Barretina sarcoma
Fibrosarcoma vs. Normal 2.236 3.44E-5 5.259 Detwiller sarcoma
MCM8 NA NA NA NA NA
MCM9 NA NA NA NA NA
MCM10 Round cell liposarcoma vs. Normal 7.893 2.81E-7 8.065 Detwiller sarcoma
Malignant fibrous histiocytoma vs. Normal 7.758 5.16E-8 7.751 Detwiller sarcoma
Synovial sarcoma vs. Normal 5.892 7.40E-6 6.531 Detwiller sarcoma
Fibrosarcoma vs. Normal 9.258 1.26E-5 6.289 Detwiller sarcoma
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to show the relationship between ONCOMINE, GEPIA,
PROGNOSIS biomarker and KEGG datasets (Figure 5C).
According to the results, we found that MCM2 and MCM4
were elevated expressed in ONCOMINE and GEPIA
datasets with prognostic values, so the key MCM family
genes including MCM2 and MCM4 were chosen to be
FIGURE 2 | The expression of MCMs in sarcoma. (A–J) The expression of MCM1-10 in pan-cancer. (K–L) The expression of MCMs in sarcoma.
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confirmed in sarcoma cell lines (Figures 5D–G). Previous study
indicated that MCM4 and MCM6-7 constituted a core structure of
MCM2-7 hexamers (Champasa et al., 2019). We found that MCM4
played a core role in all analyses (using ONCOMINE, GEPIA,
PROGNOSIS biomarker and KEGG datasets) and the differential
expression of MCM4 in osteosarcoma cell line was confirmed using
qRT-PCR and western blot, this has led us to further explore the
mechanism of prognostic value of MCM4 in sarcoma.
Methylation of MCM4 Promoter Inhibits the
Transactivation of Potential Transcription
Factors
We obtained the 5 kbMCM4 promoter sequence via the Ensembl
genome browser. CpG islands were identified using MethPrimer
software. Five CpG islands were identified in the 5 kb promoter
region (Figure 6A). The degree of methylation of CpGI three was
significantly reduced in patients with osteosarcoma (Figure 6B).
To check MCM4 gene modulation, the transcription factor
binding sites of the CpGI three were analyzed using JASPAR.
In the CpGI 3, the following transcription factors were predicted
to interact with the CpG sites: RFX5, M2F1, FOSL2, PLAG1,
RORA, PAX5, MEF2C, MZF1, E2F1, SREBF1, PAX5, and E2F4
(Figure 6C). We selected these four transcription factors with the
highest scores including SREBF1, MZF1, PAX5, and RORA for
further investigation. According to the results, we found that
transcription factors SREBF1, MZF1, PAX5, and RORA activated
MCM4-luc expression, but transcription factors SREBF1, MZF1,
PAX5 and RORA were not able to activate MCM4-luc
expression when MCM4-luc was methylated in vivo (Figures
6D–G). Additionally, we found that knockdown of these
transcription factors including SREBF1, MZF1, PAX5 and
RORA can reduce the MCM4 protein level in MG63 and
Saos-2 cell line (Figures 6H,I). The results indicated that
transactivation of potential transcription factors is affected by
methylated MCM4 promoter.
Demethylation of MCM4 on the Proliferation
and Apoptosis of hFOB1.19 Cells
Bisulfite sequencing PCR results indicated that the methylation
ratio of the MCM4 promoter decreased after AzadC treatment
(Figure 7A). The results of qRT-PCR showed that expression of
MCM4 significantly increased after AzadC treatment
(Figure 7B). We investigated if overexpression of potential
transcription factors increased demethylated MCM4 gene
expression. HFOB1.19 cells were co-transfected with potential
transcription factors. The results of qRT-PCR indicated that the
transcription factors SREBF1, MZF1, PAX5, and RORA could
activate MCM4 expression alone. When SREBF1, MZF1, PAX5,
and RORA were treated along with AzadC, the expression of
MCM4 expression increased significantly, compared with that
observed for transcription factor alone (Figures 7C–F).
FIGURE 3 | The expression of MCMs sarcoma cell lines.
Frontiers in Molecular Biosciences | www.frontiersin.org June 2021 | Volume 8 | Article 6684027
Zhou et al. Prognosis for MCMs in Sarcoma
Moreover, the CCK-8 and TUNEL experiment was conducted
to detect hFOB1.19 cellular proliferation and apoptosis after
treatment with AzadC. The results indicated that AzadC
promoted hFOB1.19 proliferation compared to control. In
order to check the MCM4 function, overexpression was
performed and the results indicated that sole overexpression of
MCM4 obtained similar results as AzadC treatment. Together,
MCM4 overexpression and AzadC treatment showed the
stronger promotion of cell proliferation, and siMCM4
decreased the effect of proliferation induced by AzadC
(Figure 7G). The TUNEL experiment results showed that
AzadC decreased the apoptosis of hFOB1.19 cells compared to
control. The sole overexpression of MCM4 obtained similar
results as AzadC treatment. Together, MCM4 overexpression
and AzadC treatment showed stronger inhibition of cell apoptosis
than the control (Figure 7H). The results showed that decreased
MCM4methylation enhanced cellular proliferation and inhibited
apoptosis in hFOB1.19 cells.
DISCUSSION
Proteins involved in the replication of DNA were widely proposed as
promising cancer biomarkers (Yu et al., 2020). MCMs family has ten
members and each of them was essential for viability. This protein
family plays an important role in different stages of DNA replication,
especially the initial step (Edwards et al., 2002; Das and Rhind, 2016).
The overexpression of MCM factors was identified in multiple
cancers, including breast cancer, lung cancer and colorectal cancer
(Gonzalez et al., 2003; Nishihara et al., 2008; Liu et al., 2017; Yu et al.,
2020). To our best knowledge, this is the first study that systematically
analyzed the expression and prognostic value of MCM factors in
human sarcoma. The study results may have important implications
for improving the prognosis of sarcoma patients.
MCM1 was reported to be localized at the replication origins
of DNA and influences the local structure of replication origins
(Chang et al., 2003). In our study, we analyzed the expression
level of MCM1 suing ONCOMINE datasets, and found that the
FIGURE 4 | The prognostic value of MCMs in patients with sarcoma. (A) The association betweenMCMgenes and overall survival in patients with sarcoma. (B) The
association between MCM genes and disease-free survival in patients with sarcoma. HR, hazard ratio; TPM, Transaction per million.
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FIGURE 5 | KEGG analysis of MCMs, crosscheck of analysis and differential expression of MCM2 and MCM4 in osteosarcoma cell lines. (A) DNA replication and
(B) cell cycle pathway regulated by the MCM alteration in sarcoma (KEGG). (C)Crosscheck of the results of ONCOMIN, GEPIA, Prognosis and KEGG analysis. Elevated
expression of (D) MCM2 and (E) MCM4 detected in osteosarcoma cell lines using qRT-PCR. Up regulated expression of (F) MCM2 and (G) MCM4 detected in
osteosarcoma cell lines using western blot, *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 6 |Methylation analysis of MCM4. (A) Five CpG islands were predicted in the MCM4 promoter region. (B) The methylation rate of CpGI3 was significantly
decreased in osteosarcoma tissues compared with the normal tumor-adjacent lung tissues. (C) A large CpG island predicted in the MCM4 promoter. (D–G) SREBF1,
MZF1, PAX5, and RORA candidate transcription factor transactivation of MCM4 expression in cell transfection experiment. Knockdown of SREBF1, MZF1, PAX5, and
RORA would reduce the MCM4 protein level in MG63 (H) and Saos-2 (I) cell lines, *p < 0.05, **p < 0.01, ***p < 0.001.
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expression level of MCM1 was higher in sarcoma tissue than in
normal tissue. But in GEPIA datasets, the result was opposite.
Then we searched the expression levels of MCM1 in the cell lines
by using CCLE datasets and found MCM1 was highly expressed in
human cell lines. With GEPIA datasets, we tried to explore the
prognostic value of MCM1 in sarcoma patients, but the result
showed that there was no significant relationship between the
expression level of MCM1 and DFS or OS of patients with sarcoma.
MCM2-7 protein complex exhibits DNA helicase activity and
plays central roles in regulating transcription, chromatin remodeling
FIGURE 7 | Cell proliferation and apoptosis analysis of MCM4 demethylation and overexpression. (A) After treatment with AzadC, MCM4 promoter methylation
level showed a significantly decreased methylation rate. (B)MCM4mRNA level significantly increased. (C–F) The activity of transcription factors (SREBF1, MZF1, PAX5,
and RORA) increased. (G) AzadC treatment and overexpression of MCM4 significantly promoted hFOB1.19 cell proliferation. SiMCM4 can decrease the effect
of hFOB1.19 cell proliferation induced by AzadC. (H) AzadC treatment and overexpression of MCM4 significantly inhibited hFOB1.19 cell apoptosis, *p < 0.05,
**p < 0.01, ***p < 0.001.
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and checkpoint responses (Ishimi, 2018). Previous studies
demonstrated that MCM2-7 protein complex could act as
biomarkers for dysplasia and malignancy (Freeman et al., 1999). It
was also showed to be prognostic markers for many kinds of human
cancers (Liu et al., 2017). We analyzed the expression levels of these
six genes in ONCOMINE datasets and GEPIA datasets, the results
showed that they were all upregulated in sarcoma compared with
normal tissues. Using CCLE datasets, we analyzed their expression
levels in sarcoma cell lines and found that they were all highly
expressed. But the prognosis value of the six genes in sarcoma was
different. With further using GEPIA datasets, we analyzed the
association between the high expression of these genes and the
OS and DSF of sarcoma patients. The results showed that high
expression ofMCM2,MCM3 andMCM4was significantly related to
poor OS of sarcoma patients. Highly expressed MCM3 was also
significantly related to poor DFS of sarcoma patients. The other three
genes had no significant relation between the expression levels and
the prognosis of sarcoma patients. So MCM2, MCM3, and MCM4
seemed to be three potential biomarkers for the prognosis of sarcoma.
MCM8–9 also formed a complex and was a homolog of the
MCM2–7 hetero-hexameric helicase complex. The resent studies
claimed that MCM8–9 played an essential role during replication
elongation and recombination of DNA (Maiorano et al., 2005;
Gambus and Blow, 2013). Cancer cells underwent more
replication stress because they were hyperstimulated to grow, and
it was reported that inhibiting MCM8-9 could increase the
sensitivity of tumors to cisplatin (Morii et al., 2019). In the
present study, we analyzed the expression levels of MCM8 and
MCM9 in ONCOMINE datasets. But there was no data about the
two factors. Then we searched their expression level in GEPIA
datasets, and the results showed that both of them were upregulated
in sarcoma compared to normal tissues. Using CCLE datasets, we
found that MCM8 and MCM9 were both overexpressed in che cell
line of sarcoma. At last, we analyzed the association between
expression levels of the two genes and the OS and DFS of
sarcoma patients, with no significant associations observed.
MCM10, an important regulator of DNA replication
initiation, was found to be crucial to maintain genome
integrity (Bielinsky, 2016). There is accumulating evidence
suggesting that in the development of tumor, dysregulation of
MCM10 contributed to aberrant proliferation and genome
instability. MCM10 was reported to play an important role in
several tumors including breast cancer and urothelial carcinoma
(Li et al., 2016; Yang and Wang, 2019). In our study, we analyzed
the expression level of MCM10 in ONCOMINE datasets and
GEPIA datasets. The results showed that MCM10 was
upregulated in sarcoma compared to normal samples. In
CCLE, we also found that MCM10 was highly expressed in
sarcoma cell lines. To explore the prognosis value of MCM10
in sarcoma, we analyzed the data in GEPIA and found that highly
expressed MCM10 was associated with poor OS of sarcoma
patients, indicating that MCM10 was a potential biomarker of
prognosis for sarcoma patients.
According to our results, we also found thatMCM4 played a core
role in ONCOMINE, GEPIA, PROGNOSIS biomarker and KEGG
analysis and the differential expression of MCM4 in osteosarcoma
cell line was confirmed using qRT-PCR and western blot. Therefore,
the mechanism of prognostic value of MCM4 in sarcoma was
explored. The results revealed that demethylation treatment
increased the transactivation of potential transcription factors and
enabled high levels of MCM4 expression in hFOB1.19 cells. CKK-8
and TUNEL experiment was conducted and the results showed that
decreased MCM4 methylation enhanced cellular proliferation and
inhibited apoptosis in hFOB1.19 cells. Therefore, the prognostic role
of MCM4 in sarcoma may be attributable to changes in DNA
methylation patterns. There was limitation in the present study. The
data used for analysis were obtained from online services. We need
to carry out more clinical experiments in a well-established tumor
cohort to confirm our findings.
CONCLUSIONS
In this study, we found that MCM2, 3, 4, and 10 could be used as
molecular markers to identify high-risk subgroups of sarcoma
patients. The four MCM family members, MCM2, 3, 4, and 10
could be prognostic biomarkers for human sarcoma and a higher
expression of these MCM factors predicts poorer outcomes. The
prognostic role of MCM4 may be attributable to changes in DNA
methylation patterns.
DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in
the article/Supplementary Material, further inquiries can be
directed to the corresponding authors.The datasets used and/
or analyzed during the current study are available from the
corresponding author on reasonable request.
AUTHOR CONTRIBUTIONS
MWconducted the western blot, qRT-PCR, Cell assay, CCK8 and
flow cytometry. JZ and GW performed ONCOMINE, GEPIA,
CCLE, Venn diagram and KEGG analysis. JZ and GW wrote the
manuscript. WW and JD edited the paper. ZZ revised the
manuscript. JZ and GW provided the research guide. All
authors read and approved the final manuscript.
FUNDING
This work was supported by the Fundamental Research Funds for
the Central Universities of Central South University (Grant No.
2018zzts930).
ACKNOWLEDGMENTS
The authors would like to especially thank MW from Soochow
University for his experimental support including western blot,
qRT-PCR, cell assay, CCK8 and flow cytometry. The authors
thank ZZ for English language support in preparing manuscript.
Frontiers in Molecular Biosciences | www.frontiersin.org June 2021 | Volume 8 | Article 66840212
Zhou et al. Prognosis for MCMs in Sarcoma
REFERENCES
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A.H., Lagos-Quintana,M., DeCarolis, P.
L., et al. (2010). Subtype-specific Genomic Alterations Define New Targets for
Soft-Tissue Sarcoma Therapy. Nat. Genet. 42, 715–721. doi:10.1038/ng.619
Baxley, R., and Bielinsky, A.-K. (2017). Mcm10: A Dynamic Scaffold at Eukaryotic
Replication forks. Genes 8, 73. doi:10.3390/genes8020073
Bielinsky, A.-K. (2016). Mcm10: The Glue at Replication forks. Cell Cycle 15,
3024–3025. doi:10.1080/15384101.2016.1216925
Cai, H.-Q., Cheng, Z.-J., Zhang, H.-P., Wang, P.-F., Zhang, Y., Hao, J.-J., et al.
(2018). Overexpression of MCM6 Predicts Poor Survival in Patients with
Glioma. Hum. Pathol. 78, 182–187. doi:10.1016/j.humpath.2018.04.024
Champasa, K., Blank, C., Friedman, L. J., Gelles, J., and Bell, S. P. (2019). A
Conserved Mcm4 Motif Is Required for Mcm2-7 Double-Hexamer Formation
and Origin DNA Unwinding. Elife 8. e45538. doi:10.7554/eLife.45538
Chang, V. K., Fitch, M. J., Donato, J. J., Christensen, T. W., Merchant, A. M., and
Tye, B. K. (2003). Mcm1 Binds Replication Origins. J. Biol. Chem. 278,
6093–6100. doi:10.1074/jbc.M209827200
Dancsok, A. R., Asleh-Aburaya, K., and Nielsen, T. O. (2017). Advances in Sarcoma
Diagnostics and Treatment.Oncotarget 8, 7068–7093. doi:10.18632/oncotarget.12548
Das, S. P., and Rhind, N. (2016). How and Why Multiple MCMs Are Loaded at
Origins of DNA Replication. Bioessays 38, 613–617. doi:10.1002/bies.201600012
Detwiller, K. Y., Fernando, N. T., Segal, N. H., Ryeom, S. W., D’Amore, P. A., and
Yoon, S. S. (2005). Analysis ofHypoxia-Related Gene Expression in Sarcomas and
Effect of Hypoxia on RNA Interference of Vascular Endothelial Cell Growth
Factor a. Cancer Res. 65, 5881–5889. doi:10.1158/0008-5472.CAN-04-4078
Edwards, M. C., Tutter, A. V., Cvetic, C., Gilbert, C. H., Prokhorova, T. A.,
and Walter, J. C. (2002). MCM2-7 Complexes Bind Chromatin in a
Distributed Pattern Surrounding the Origin Recognition Complex
inXenopus Egg Extracts. J. Biol. Chem. 277, 33049–33057. doi:10.1074/
jbc.M204438200
Fei, L., and Xu, H. (2018). Role of MCM2-7 Protein Phosphorylation in Human
Cancer Cells. Cell Biosci. 8, 43. doi:10.1186/s13578-018-0242-2
Freeman, A., Morris, L. S., Mills, A. D., Stoeber, K., Laskey, R. A., Williams, G. H.,
et al. (1999). Minichromosome Maintenance Proteins as Biological Markers of
Dysplasia and Malignancy. Clin. Cancer Res. 5, 2121–2132.
Gambus, A., and Blow, J. J. (2013). Mcm8 and Mcm9 Form a Dimeric Complex
inXenopus Laevisegg Extract that Is Not Essential for DNA Replication
Initiation. Cell Cycle 12, 1225–1232. doi:10.4161/cc.24310
Giaginis, C., Georgiadou, M., Dimakopoulou, K., Tsourouflis, G., Gatzidou, E.,
Kouraklis, G., et al. (2009). Clinical Significance of MCM-2 and MCM-5
Expression in colon Cancer: Association with Clinicopathological
Parameters and Tumor Proliferative Capacity. Dig. Dis. Sci. 54, 282–291.
doi:10.1007/s10620-008-0305-z
Gonzalez, M. A., Pinder, S. E., Callagy, G., Vowler, S. L., Morris, L. S., Bird, K., et al.
(2003). Minichromosome Maintenance Protein 2 Is a strong Independent
Prognostic Marker in Breast Cancer. J. Clin. Oncol. 21, 4306–4313.
doi:10.1200/JCO.2003.04.121
Griffin, W. C., and Trakselis, M. A. (2019). The MCM8/9 Complex: A Recent
Recruit to the Roster of Helicases Involved in Genome Maintenance. DNA
Repair 76, 1–10. doi:10.1016/j.dnarep.2019.02.003
Ishimi, Y. (2018). Regulation of MCM2-7 Function.Genes Genet. Syst. 93, 125–133.
doi:10.1266/ggs.18-00026
Li, S., Jiang, Z., Li, Y., and Xu, Y. (2019). Prognostic Significance of
Minichromosome Maintenance mRNA Expression in Human Lung
Adenocarcinoma. Oncol. Rep. 42, 2279–2292. doi:10.3892/or.2019.7330
Li, W.-M., Huang, C.-N., Ke, H.-L., Li, C.-C., Wei, Y.-C., Yeh, H.-C., et al. (2016).
MCM10 Overexpression Implicates Adverse Prognosis in Urothelial
Carcinoma. Oncotarget 7, 77777–77792. doi:10.18632/oncotarget.12795
Liu, Y.-Z., Wang, B.-S., Jiang, Y.-Y., Cao, J., Hao, J.-J., Zhang, Y., et al. (2017).
MCMs Expression in Lung Cancer: Implication of Prognostic Significance.
J. Cancer 8, 3641–3647. doi:10.7150/jca.20777
Maiorano, D., Cuvier, O., Danis, E., and Méchali, M. (2005). MCM8 Is an MCM2-
7-Related Protein that Functions as a DNA Helicase during Replication
Elongation and Not Initiation. Cell 120, 315–328. doi:10.1016/j.cell.2004.12.010
Maiorano, D., Lutzmann, M., and Méchali, M. (2006). MCM Proteins and DNA
Replication. Curr. Opin. Cel Biol. 18, 130–136. doi:10.1016/j.ceb.2006.02.006
Marnerides, A., Vassilakopoulos, T. P., Boltetsou, E., Levidou, G., Angelopoulou,
M. K., Thymara, I., et al. (2011). Immunohistochemical Expression and
Prognostic Significance of CCND3, MCM2 and MCM7 in Hodgkin
Lymhoma. Anticancer Res. 31, 3585–3594.
Morii, I., Iwabuchi, Y., Mori, S., Suekuni, M., Natsume, T., Yoshida, K., et al.
(2019). Inhibiting the MCM8-9 Complex Selectively Sensitizes Cancer Cells
to Cisplatin and Olaparib. Cancer Sci. 110, 1044–1053. doi:10.1111/
cas.13941
Nishihara, K., Shomori, K., Fujioka, S., Tokuyasu, N., Inaba, A., Osaki, M., et al. (2008).
Minichromosome Maintenance Protein 7 in Colorectal Cancer: Implication of
Prognostic Significance. Int. J. Oncol. 33, 245–251. doi:10.3892/ijo_00000003
Peng, Y.-P., Zhu, Y., Yin, L.-D., Zhang, J.-J., Guo, S., Fu, Y., et al. (2016). The
Expression and Prognostic Roles of MCMs in Pancreatic Cancer. PLoS One 11,
e0164150. doi:10.1371/journal.pone.0164150
Pramila, T., Miles, S., GuhaThakurta, D., Jemiolo, D., and Breeden, L. L. (2002).
Conserved Homeodomain Proteins Interact with MADS Box Protein Mcm1 to
Restrict ECB-dependent Transcription to the M/G1 Phase of the Cell Cycle.
Genes Dev. 16, 3034–3045. doi:10.1101/gad.1034302
Quade, B. J., Wang, T.-Y., Sornberger, K., Cin, P. D., Mutter, G. L., and Morton, C.
C. (2004). Molecular Pathogenesis of Uterine Smooth Muscle Tumors from
Transcriptional Profiling. Genes Chromosom. Cancer 40, 97–108. doi:10.1002/
gcc.20018
Rusiniak, M. E., Kunnev, D., Freeland, A., Cady, G. K., and Pruitt, S. C. (2012).
Mcm2 Deficiency Results in Short Deletions Allowing High Resolution
Identification of Genes Contributing to Lymphoblastic Lymphoma.
Oncogene 31, 4034–4044. doi:10.1038/onc.2011.566
Shomori, K., Nishihara, K., Tamura, T., Tatebe, S., Horie, Y., Nosaka, K., et al.
(2010). Geminin, Ki67, and Minichromosome Maintenance 2 in Gastric
Hyperplastic Polyps, Adenomas, and Intestinal-type Carcinomas:
Pathobiological Significance. Gastric Cancer 13, 177–185. doi:10.1007/
s10120-010-0558-z
Stewart, P. A., Khamis, Z. I., Zhau, H. E., Duan, P., Li, Q., Chung, L. W. K., et al.
(2017). Upregulation of Minichromosome Maintenance Complex Component
3 during Epithelial-To-Mesenchymal Transition in Human Prostate Cancer.
Oncotarget 8, 39209–39217. doi:10.18632/oncotarget.16835
Suzuki, Y., Yamaguchi, Y., Hanada, H., and Ishimi, Y. (2019). Changes in MCM2-7
Proteins at Senescence. Genes Genet. Syst. 94, 123–132. doi:10.1266/ggs.18-
00062
Winther, T. L., and Torp, S. H. (2017). MCM7 Expression Is a Promising Predictor
of Recurrence in Patients Surgically Resected for Meningiomas. J. Neurooncol.
131, 575–583. doi:10.1007/s11060-016-2329-0
Wojnar, A., Pula, B., Piotrowska, A., Jethon, A., Kujawa, K., Kobierzycki, C., et al.
(2011). Correlation of Intensity of MT-I/II Expression with Ki-67 and MCM-2
Proteins in Invasive Ductal Breast Carcinoma. Anticancer Res. 31, 3027–3033.
Wu, W., Wang, X., Shan, C., Li, Y., and Li, F. (2018). Minichromosome
Maintenance Protein 2 Correlates with the Malignant Status and Regulates
Proliferation and Cell Cycle in Lung Squamous Cell Carcinoma. Onco. Targets
Ther. 11, 5025–5034. doi:10.2147/OTT.S169002
Yang, W. D., and Wang, L. (2019). MCM10 Facilitates the Invaded/migrated
Potentials of Breast Cancer Cells via Wnt/β-catenin Signaling and Is Positively
Interlinked with Poor Prognosis in Breast Carcinoma. J. Biochem. Mol. Toxicol.
33, e22330. doi:10.1002/jbt.22330
Yu, S., Wang, G., Shi, Y., Xu, H., Zheng, Y., and Chen, Y. (2020). MCMs in Cancer:
Prognostic Potential and Mechanisms. Anal. Cell Pathol. 2020, 1–11.
doi:10.1155/2020/3750294
Zhong, H., Chen, B., Neves, H., Xing, J., Ye, Y., Lin, Y., et al. (2017). Expression of
Minichromosome Maintenance Genes in Renal Cell Carcinoma. Cancer
Manag. Res. 9, 637–647. doi:10.2147/CMAR.S146528
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Zhou, Wang, Zhou, Wang, Duan and Wu. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
Frontiers in Molecular Biosciences | www.frontiersin.org June 2021 | Volume 8 | Article 66840213
Zhou et al. Prognosis for MCMs in Sarcoma
